Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting.
Crit Rev Oncol Hematol
; 202: 104472, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-39111458
ABSTRACT
Antibody-drug conjugates (ADCs) have high specificity with lesser off-target effects, thus providing improved efficacy over traditional chemotherapies. A total of 14 ADCs have been approved for use against cancer by the US Food and Drug Administration (FDA), with more than 100 ADCs currently in clinical trials. Of particular interest ADCs targeting immune antigens PD-L1, B7-H3, B7-H4 and integrins. Specifically, we describe ADCs in development along with the gene and protein expression of these immune checkpoints across a wide range of cancer types let url = window.clickTag || window.clickTag1 || window.clickTag2 || window.clickTag3 || window.clickTag4 || window.bsClickTAG || window.bsClickTAG1 || window.bsClickTAG2 || window.url || ''; if(typeof url == 'string'){ document.body.dataset['perxceptAdRedirectUrl'] = url;}.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunoconjugates
/
Immunotherapy
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Crit Rev Oncol Hematol
Year:
2024
Document type:
Article